196 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
, partially offset by an increase in R&D expenses due to the Novan acquisition. General and administrative expenses were $52.8 million for 2023 … discrete tax benefit related to the release of FIN48 reserves associated with certain R&D tax credits during the fourth quarter of 2023 due to the lapse
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Sep 23
Departure of Directors or Certain Officers
8:38am
of the Board’s nominating and corporate governance committee.
Ms. Zimmermann, 55, has been Senior Vice President and Head of Regulatory Affairs and R&D Quality
8-K
EX-99.1
ey71ufmreb1c6fvj
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
425
EX-99.1
qvtfb ddzv
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
yy5l1oi aip9
21 Jun 22
Regulation FD Disclosure
6:19am
425
194 kum3nj4wf
5 May 22
Business combination disclosure
7:30am
8-K
EX-99.1
afun5854nmh 97ey
4 May 22
Ligand Reports First Quarter 2022 Financial Results
4:03pm
425
EX-99.2
x8gd572emzt4811
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.3
fmm0od
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
6vf mkt5ea3z3o7z
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
wvqlad 5ocbjvutsyd2
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm